Takara Bio Inc. Announces Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Earnings Forecast for the Year Ending March 31, 2019
November 06, 2018 at 03:00 am
Share
Takara Bio Inc. announced unaudited consolidated earnings results for the six months ended September 30, 2018. For the period, net sales were JPY 17,370 million compared to JPY 14,126 million a year ago. Operating income was JPY 2,623 million compared to JPY 688 million a year ago. Income before income taxes and minority interests was JPY 2,436 million against JPY 749 million a year ago. Net income was 1,717 million against JPY 299 million a year ago. Net income per share was JPY 14.29 compared to JPY 2.51 per share a year ago.
The company also provided the earnings forecast for the year ending March 31, 2019. For the year, the company expecting a net sales of JPY 35,800 million, Operating income of 5,000 million, net income attributable to owner of parent of JPY 3,100 million and net income attributable to owner of parent per share of JPY 25.74.
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Takara Bio Inc. Announces Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Earnings Forecast for the Year Ending March 31, 2019